- Home
- ACCS vs OTLK Comparison
ACCS vs OTLK Comparison
Compare ACCS & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACCS
- OTLK
- Stock Information
- Founded
- ACCS 1988
- OTLK 2010
- Country
- ACCS United States
- OTLK United States
- Employees
- ACCS N/A
- OTLK N/A
- Industry
- ACCS Publishing
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACCS Consumer Discretionary
- OTLK Health Care
- Exchange
- ACCS Nasdaq
- OTLK Nasdaq
- Market Cap
- ACCS 42.6M
- OTLK 42.8M
- IPO Year
- ACCS N/A
- OTLK 2016
- Fundamental
- Price
- ACCS $9.58
- OTLK $1.34
- Analyst Decision
- ACCS Strong Buy
- OTLK Buy
- Analyst Count
- ACCS 1
- OTLK 5
- Target Price
- ACCS $14.00
- OTLK $5.25
- AVG Volume (30 Days)
- ACCS 6.6K
- OTLK 1.9M
- Earning Date
- ACCS 11-11-2025
- OTLK 08-14-2025
- Dividend Yield
- ACCS N/A
- OTLK N/A
- EPS Growth
- ACCS N/A
- OTLK N/A
- EPS
- ACCS N/A
- OTLK N/A
- Revenue
- ACCS $22,562,000.00
- OTLK $1,505,322.00
- Revenue This Year
- ACCS $0.03
- OTLK N/A
- Revenue Next Year
- ACCS $11.45
- OTLK $342.80
- P/E Ratio
- ACCS N/A
- OTLK N/A
- Revenue Growth
- ACCS 26.44
- OTLK N/A
- 52 Week Low
- ACCS $7.79
- OTLK $0.79
- 52 Week High
- ACCS $13.35
- OTLK $6.98
- Technical
- Relative Strength Index (RSI)
- ACCS 32.02
- OTLK 54.24
- Support Level
- ACCS $9.40
- OTLK $1.28
- Resistance Level
- ACCS $9.99
- OTLK $1.48
- Average True Range (ATR)
- ACCS 0.40
- OTLK 0.11
- MACD
- ACCS -0.04
- OTLK 0.01
- Stochastic Oscillator
- ACCS 0.83
- OTLK 52.78
About ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.